Synthetic abnormal mast cell particles successfully mimic neoplastic mast cells by flow cytometry

Author:

Davis Patricia M.1ORCID,Ravkov Eugene1,de Geus Martina2,Clauss Zach2,Lee John2,Nguyen Anh Tuan2,Hartmann Marsha2,Kim Jeffrey2,George Tracy I.13,Lin Leo13,Ng David P.13ORCID

Affiliation:

1. ARUP Institute for Clinical & Experimental Pathology, ARUP Laboratories Salt Lake City Utah USA

2. Slingshot Biosciences Emeryville California USA

3. Department of Pathology University of Utah Salt Lake City Utah USA

Abstract

AbstractClinical flow cytometry laboratories require quality control materials for assay development, validation, and performance monitoring, including new reagent lot qualification. However, finding suitable controls for populations with uncommonly expressed antigens or for rare populations, such as mast cells, can be difficult. To that end, we evaluated synthetic abnormal mast cell particles (SAMCP), developed together with, and manufactured by, Slingshot Biosciences. The SAMCP's were designed to phenotypically mimic abnormal neoplastic mast cells: they were customized to have the same light scatter and autofluorescence properties of mast cells, along with surface antigen levels of CD45, CD33, CD117, CD2, CD25, and CD30 consistent with that seen in mast cell disease. We evaluated several performance characteristics of these particles using ARUP's high sensitivity clinical mast cell assay, including limit of detection, off‐target activity and FMO controls, precision, scatter properties of the particles utilizing several different cytometer platforms, and particle antigen stability. The phenotype of the SAMCP mimicked abnormal mast cells, and they could be distinguished from normal native mast cells. FMO controls demonstrated specificity of each of the markers, and no off‐target binding was detected. The limit of detection of the particles spiked into normal bone marrow was found to be ≤0.003% in a limiting dilution assay. The mast cell particles were found to perform similarly on Becton Dickinson Lyric, Cytek Aurora, and Beckman Coulter Navios and CytoFLEX platforms. Within run and between run precision were less than 10% CV. SAMCP were stable up to 13 days with minimal loss of antigen fluorescence intensity. The SAMCP's were able to successfully mimic neoplastic mast cells based on the results of our high sensitivity mast cell flow cytometry panel. These synthetic cell particles represent an exciting and innovative technology, which can fulfill vital needs in clinical flow cytometry such as serving as standardized control materials for assay development and performance monitoring.

Publisher

Wiley

Reference8 articles.

1. Epidemiology, prognosis, and risk factors in mastocytosis;Brockow K.;Immunology and Allergy Clinics of North America,2014

2. Comparison of three methods to stabilize bronchoalveolar lavage cells for flowcytometric analysis;Eidhof H. H. M.;Cytometry. Part B, Clinical Cytometry,2021

3. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols;Kalina T.;Leukemia,2012

4. Harmonization and standardization: Where are we now?;Miller W. G.;Journal of Applied Laboratory Medicine,2021

5. Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: Identification and enumeration;Orfao A.;The American Journal of Pathology,1996

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3